# ACR-ABS-ARS PRACTICE PARAMETER FOR THE PERFORMANCE OF RADIONUCLIDE-BASED HIGH-DOSE-RATE BRACHYTHERAPY

The American College of Radiology, with more than 40,000 members, is the principal organization of radiologists, radiation oncologists, and clinical medical physicists in the United States. The College is a nonprofit professional society whose primary purposes are to advance the science of radiology, improve radiologic services to the patient, study the socioeconomic aspects of the practice of radiology, and encourage continuing education for radiologists, radiation oncologists, medical physicists, and persons practicing in allied professional fields.

The American College of Radiology will periodically define new practice parameters and technical standards for radiologic practice to help advance the science of radiology and to improve the quality of service to patients throughout the United States. Existing practice parameters and technical standards will be reviewed for revision or renewal, as appropriate, on their fifth anniversary or sooner, if indicated.

Each practice parameter and technical standard, representing a policy statement by the College, has undergone a thorough consensus process in which it has been subjected to extensive review and approval. The practice parameters and technical standards recognize that the safe and effective use of diagnostic and therapeutic radiology requires specific training, skills, and techniques, as described in each document. Reproduction or modification of the published practice parameter and technical standard by those entities not providing these services is not authorized.

#### **PREAMBLE**

Radiologists, medical physicists, non-physician radiology providers, radiologic technologists, and all supervising physicians have a responsibility for safety in the workplace by keeping radiation exposure to staff, and to society as a whole, "as low as reasonably achievable" (ALARA) and to assure that radiation doses to individual patients are appropriate, taking into account the possible risk from radiation exposure and the diagnostic image quality necessary to achieve the clinical objective. All personnel who work with ionizing radiation must understand the key principles of occupational and public radiation protection (justification, optimization of protection, application of dose constraints and limits) and the principles of proper management of radiation dose to patients (justification, optimization including the use of dose reference levels). <a href="https://www-pub.iaea.org/MTCD/Publications/PDF/PUB1775\_web.pdf">https://www-pub.iaea.org/MTCD/Publications/PDF/PUB1775\_web.pdf</a>

Facilities and their responsible staff should consult with the radiation safety officer to ensure that there are policies and procedures for the safe handling and administration of radiopharmaceuticals in accordance with ALARA principles. These policies and procedures must comply with all applicable radiation safety regulations and conditions of licensure imposed by the Nuclear Regulatory Commission (NRC) and by applicable state, local, or other relevant regulatory agencies and accrediting bodies, as appropriate. Quantities of radiopharmaceuticals should be tailored to the individual patient by prescription or protocol, using body habitus or other customized method when such guidance is available.

Nationally developed guidelines, such as the <u>ACR's Appropriateness Criteria</u>®, should be used to help choose the most appropriate imaging procedures to prevent unnecessary radiation exposure.

Additional information regarding patient radiation safety in imaging is available from the following websites – Image Gently® for children (<a href="www.imagegently.org">www.imagegently.org</a>) and Image Wisely® for adults (<a href="www.imagewisely.org">www.imagewisely.org</a>). These advocacy and awareness campaigns provide free educational materials for all stakeholders involved in imaging (patients, technologists, referring providers, medical physicists, and radiologists).

Radiation exposures or other dose indices should be periodically measured by a Qualified Medical Physicist in accordance with the applicable ACR Technical Standards. Monitoring or regular review of dose indices from patient imaging should be performed by comparing the facility's dose information with national benchmarks, such as the ACR Dose Index Registry and relevant publications relying on its data, applicable ACR Practice Parameters, NCRP Report No. 172, Reference Levels and Achievable Doses in Medical and Dental Imaging: Recommendations for the United States or the Conference of Radiation Control Program Director's National Evaluation of X-ray Trends; 2006, 2009, amended 2013, revised 2023 (Res. 2d).

### I. INTRODUCTION

This practice parameter was revised collaboratively by the American College of Radiology (ACR), the American Brachytherapy Society (ABS), and the American Radium Society (ARS).

Brachytherapy is a radiotherapeutic method in which radionuclide or electronic sources are used to deliver a radiation dose to a treatment site (target) up to a few centimeters from the source by surface, intracavitary, intraluminal, or interstitial application. This practice parameter refers only to the use of radionuclides for brachytherapy. Brachytherapy alone or combined with external-beam radiotherapy plays an important role in the management and treatment of patients with cancer [1]. High-dose-rate (HDR) brachytherapy uses

radionuclides such as iridium-192 at dose rates of 20 cGy/min (12 Gy/hr) or more to a designated target point or volume. HDR brachytherapy is indicated for treating invasive tumors where the treatment volume or targeted points are defined and accessible.

The use of brachytherapy requires detailed attention to personnel, equipment, patient and personnel safety, and continuing staff education.

The licensing of radioactive sources (radionuclides) and the safety of the general public and health care workers are regulated by the Nuclear Regulatory Commission (NRC) or by agreement states<sup>1</sup>. Medical use of radionuclides for therapeutic procedures must adhere to the constraints set forth by these regulatory agencies. Detailed descriptions of NRC licensing and safety issues can be found in the Code of Federal Regulations, Part 20 and Part 35. State requirements for the agreement states are found in the respective state statutes and regulations.

A literature search was performed and reviewed to identify published articles regarding practice parameters and technical standards in HDR brachytherapy.

<sup>1</sup> An agreement state is any state with which the US Nuclear Regulatory Commission or the US Atomic Energy Commission has entered into an effective agreement under Subsection 274.b of the Atomic Energy Act of 1954, as amended (73 Stat. 689).

## **II. PROCESS OF BRACHYTHERAPY**

The use of HDR brachytherapy is a complex multistep process involving trained personnel who must work in concert to carry out a variety of interrelated activities. Communication among brachytherapy team members and well-defined procedures are essential for accurate and safe treatment. See the <u>ACR–ARS Practice Parameter for Communication</u>: Radiation Oncology[2].

## A. Clinical Evaluation

The initial evaluation of the patient includes history, physical examination, review of ongoing diagnostic studies and reports, and communication with the referring physician and other physicians involved in the patient's care. The extent of the disease must be determined and recorded for staging. Staging facilitates treatment decisions, determines the prognosis of the patient, and enables a comparison of treatment results. When applicable, studies are performed to assess treatment response. The brachytherapy treatment target and organs at risk should be identified and documented as part of the clinical evaluation. See the <u>ACR-ARS Practice Parameter for Radiation Oncology</u> [3] and the <u>ACR-ARS Practice Parameter for Communication: Radiation Oncology</u> [2].

## **B.** Establishing Treatment Goals

The goals of radiotherapy should be clearly documented. Treatment options and their relative benefits and risks should be discussed with the patient. The role of integrating other therapies, such as external-beam therapy, chemotherapy, immunotherapies, or hormonal manipulation, with brachytherapy must be consulted and discussed when defining the course of treatment. A summary of the evaluation should be communicated to the referring physician and other physicians involved in the patients's care.

## C. Informed Consent

Informed consent must be obtained and documented. See the <u>ACR-ARS Practice Parameter on Informed Consent – ??Radiation Oncology</u> [4].

## D. Applicator Placement

Oncologic practice, including brachytherapy, may require the interaction of multiple specialists. The choice and placement of afterloading applicators, treatment planning, and treatment delivery are the responsibility of the radiation oncologist who is a licensed authorized user of radionuclides for medical purposes[5].

Each type of brachytherapy procedure has unique characteristics. The brachytherapy team should operate according to an established procedural system that has been developed by the radiation oncologist and brachytherapy team members. This systematic approach to applicator insertion and source afterloading should include a description of preimplantation procedures, sedation or anesthesia needs, applicator option, and insertion techniques. Standard orders or care guidelines may enhance the systematic approach to the brachytherapy process. The physician should be responsible for applicator removal, including supervision or oversight of applicator removal if done by a trained member of the brachytherapy team.

## E. Image Acquisition

In most applications, images of the implanted regions should be obtained. Imaging should be standardly performed for treatment planning and/ or to verify intended applicator position for intracavitary, interstitial, intraluminal, and complex surface brachytherapy. In certain instances (ie, simple surface brachytherapy), clinical assessments without radiographic images may suffice for verification of applicator position, and clinical photography is encouraged in such situations. Images may be either 2-D (radiography based) or 3-D (ultrasound, computed tomography, or magnetic resonance imaging based). The authorized user should select the optimal imaging protocols for treatment planning. These protocols acquire optimal images of the implant applicator, the treatment target, and the surrounding normal tissues. It is desirable to have 3-D spatial information so that the relationship of the target and surrounding critical organs can be visualized. The dose applied to the target and to the normal critical structures can then be determined and optimized. For instance, to help mitigate localization uncertainties, CT or MRI slice thicknesses on the order of 1 to 2 mm should be considered. Optimization of the diagnostic and functional imaging protocols in collaboration with diagnostic radiologists, nuclear medicine physicians, and imaging physicists is critical.

## F. Treatment Planning

As the authorized user, the radiation oncologist must provide a signed and dated written directive (WD) to the planner (ie, Qualified Medical Physicist, certified medical dosimetrist), as described in the regulations applicable to your state. The WD should include at least the treatment site, the radionuclide used, the dose per fraction, the total number of fractions, the planned total dose, and the dose specification (ie, target volume, point, distance from lumen, or surface of applicator) as per NRC 10 CFR 35.40[6]. Based on anatomical targets/organs at risk (OARs) as well as dose specifications, the treatment planner creates a treatment plan. Computer-planning techniques to shape the dose distribution are widely available and should be used correctly to properly optimize the dosimetry in all visualized planes. Verification of the resultant plan's dosimetric calculations must be performed using a secondary dose calculation prior to treatment delivery (see Section V). Once the radiation oncologist has reviewed and approved the plan and final adjustment to the WD (prescription) parameters has been made, the plan must be saved and locked using a unique user identification and password combination to prevent any unintended changes.

# G. Treatment Delivery

Time-out: Verification of patient identity is required prior to treatment delivery. A time-out should be performed and documented in the medical record prior to treatment delivery. At a minimum, the time-out should include patient identity, treatment site, laterality if applicable, dose per fraction, and fraction number of the total course.

Prior to each treatment, the radiation oncologist, Qualified Medical Physicist, or the radiation therapist should verify and document that the HDR afterloader transfer tubes are appropriately connected to each applicator channel. The patient and the room must be surveyed with pre-treatment survey results documented in the patient records. The Qualified Medical Physicist should verify and document all treatment parameters at the HDR treatment console prior to source delivery, including the correspondence between planned source strength and afterloader source strength with appropriate corrections for source decay. In a multi-fraction treatment regimen using indwelling needles or catheters, where interfraction movement is possible, it is important to verify that the applicator is stable with regards to the target and OARs before delivery of subsequent fractions. In any single-fraction treatment it is also important to verify applicator positioning prior to treatment. Verification of applicator position can be performed by visualizing the applicator relative to the patient and/or with 2-D or 3-D imaging.

Radiation safety measures are mandatory for HDR procedures to ensure exposure is confined to the patient and that the source is properly delivered and returned to the radiation safe location within the afterloader. The radiation oncologist and the Qualified Medical Physicist must be in the immediate vicinity at all times while HDR brachytherapy is being administered. The patient must be continuously monitored by video and/or audio means during treatment, and the proper functioning of equipment must be supervised by the qualified personnel. Treatment delivery must be documented for each fraction and subject to detailed examination as described in the patient and personnel safety section (see Section VI). At the end of each treatment, the patient and the room must be surveyed to confirm the source has been safely retracted into the afterloading device. The radiation survey results should be recorded and maintained per regulatory requirements.

# H. Treatment Summary

At the conclusion of the course of treatment, a written treatment summary that includes a description of the brachytherapy technique/applicator(s), dose per fraction, number of fractions, total brachytherapy dose, cumulative dose to the target and OAR, and dose specification and total dose of external-beam radiotherapy, if given, should be generated. There should also be a brief outline of the clinical course, acute toxicities or procedure complications, if any, and a plan for patient follow-up care. See the <u>ACR–ARS</u> <u>Practice Parameter for Communication: Radiation Oncology</u> [2].

## I. Follow-up Evaluation

Patients treated with HDR brachytherapy should be evaluated at regular intervals for disease status, procedure-related side effects, and radiation complications. Information about the patient's clinical status should be communicated to the primary, referring, and other appropriate physician(s).

## J. Emergency Procedures

Emergency procedures that outline the actions taken by the radiation oncologist, Qualified Medical Physicist, radiation safety officer, and any additional members of the treatment team in the event a radioactive source does not retract, as planned, from the patient at the end of HDR delivery must be defined. Emergency procedures should be reviewed and documented with each member of the brachytherapy team at least annually.

# **III. QUALIFICATIONS OF PERSONNEL**

The HDR brachytherapy team includes the radiation oncologist, Qualified Medical Physicist, dosimetrist, radiation therapist, and/or nurse. An individual serving in the role of radiation safety officer should provide an independent regulatory oversight. HDR brachytherapy requires close coordination between all members of the team as radiation is given in relatively large doses per fraction in a short period of time. Errors in treatment leading to radiation misadministration can happen quickly with serious consequences. Communication among team members and well-defined procedures for performing HDR brachytherapy are thus essential for accurate and safe treatment. Qualifications of the brachytherapy team include the credentials listed below.

A. Radiation Oncologist who also meets the requirements of the Authorized User[5]
Certification in Radiology in Radiation Oncology or Therapeutic Radiology by the American Board of
Radiology, the American Osteopathic Board of Radiology, the Royal College of Physicians and Surgeons of
Canada (RCPSC), or the Collège des Médecins du Québec, or certification in Radiology by the American
Board of Radiology of a physician who confines his/her professional practice to radiation oncology.

or

Satisfactory completion of a residency program in radiation oncology approved by the Accreditation Council for Graduate Medical Education (ACGME), the RCPSC, the Collège des Médecins du Québec, or the American Osteopathic Association (AOA).

# B. Qualified Medical Physicist

For the qualifications of the Qualified Medical Physicist, see the <u>ACR-AAPM Technical Standard for the Performance of High-Dose-Rate Brachytherapy Physics</u> [7].

## C. Medical Dosimetrist

Board certification by the Medical Dosimetrist Certification Board is highly recommended.

#### D. Radiation Therapist

The radiation therapist must fulfill state licensing requirements and should have American Registry of Radiologic Technologists (ARRT) certification in radiation therapy.

#### E. Nurse

The nurse must fulfill state licensing requirements.

## **Continuing Education Program**

Continuing medical education (CME) programs should include radiation oncologists, Qualified Medical Physicists, dosimetrists, radiation therapists, nurses, and radiotherapy staff. Radiation safety programs should also include hospital-based personnel who will be involved with brachytherapy patients. Educational programs used for both initial training and retraining must cover the following:

- The safe operation, including emergency procedures, of HDR applicators and HDR remote afterloading equipment and sources as appropriate to the individual's responsibilities.
- Treatment techniques and new developments in radiation oncology and brachytherapy
- The program should be in accordance with the <u>ACR Practice Parameter for Continuing Medical Education</u> (<u>CME</u>) [-3197622]

The Medical Director of Radiation Oncology is responsible for the institution and ongoing supervision of continuing quality improvement (CQI) as described in the <u>ACR–ARS Practice Parameter for Radiation Oncology</u>[-3197883]. It is the responsibility of the Director to identify problems, ensure that actions are taken, and evaluate the effectiveness of the actions. The Director will designate appropriate personnel to constitute the CQI Committee that will review HDR brachytherapy as part of the CQI meeting agenda. Refer to the <u>ACR–ARS Practice Parameter for Radiation Oncology</u>[-3197883] for a detailed description of CQI Committee functions.

# IV. PATIENT SELECTION CRITERIA

# A. Cervical Cancer

Brachytherapy is an essential modality in the definitive treatment of cervical cancer as there is improved survival compared with advanced techniques of external-beam radiotherapy [8, 9]. Brachytherapy is given in conjunction with external-beam radiotherapy with or without concurrent for chemotherapy locally advanced cervical cancer. Omission of chemotherapy can be considered for patients with early-stage disease in whom radical hysterectomy is medically contraindicated. International randomized trials and meta analyzes have concluded that HDR brachytherapy is equivalent to low-dose-rate (LDR) brachytherapy for local control, survival, and toxicity. Treatment planning is an integral part of cervical cancer brachytherapy because of the need for high curative doses to the cervix and paracervical tumor and the close proximity of the normal pelvic organs. 3-D image-based brachytherapy should be performed with the applicator in place, preferably with incorporation of MRI given the superior soft-tissue delineation of the clinical target volume [10]. MRI may be performed at a time prior to applicator placement with incorporation of findings into a CT-based treatment plan, or, more ideally, MRI may be performed with the applicator in place. A high-risk clinical target volume (HR-CTV) is commonly generated for dose specification, which consists of residual gross disease, cervix, and regions of regressed disease with intermediate signal on T2-weighted MRI (gray zones) [11]. If MRI cannot be performed proximate to the time of implant, then 3-D imaging with CT or ultrasound should be utilized to delineate the target volume.

Cervical brachytherapy is most commonly delivered with intracavitary applicators with or without interstitial needles. For more advanced disease, brachytherapy may also be delivered with a perineal template or free-hand technique with interstitial needles and an intrauterine tandem. Intracavity or interstitial brachytherapy is used postoperatively in some patients following hysterectomy [11-24].

## B. Endometrial Cancer

Vaginal brachytherapy, with or without external-beam radiotherapy, is frequently used following surgical staging in the treatment of patients with early endometrial carcinoma. Vaginal brachytherapy is an effective means of reducing the risk of a vaginal recurrence with a low risk of morbidity. Brachytherapy is also used for patients with recurrent endometrial carcinoma and, in this setting, application may be intracavitary or interstitial based on tumor thickness and depth of invasion. Brachytherapy is routinely used following external-beam radiotherapy in previously unirradiated patients with recurrent disease. Definitive radiotherapy with brachytherapy with or without external-beam radiotherapy may be considered for patients with medically inoperable endometrial carcinoma [13, 15-21].

## C. Vaginal Cancer

Brachytherapy is used alone or in combination with external-beam radiotherapy with or without chemotherapy concurrent in the curative treatment of cancers of the vagina. Depending on the extent of initial disease and residual disease following external-beam radiotherapy, brachytherapy may be either intracavitary or interstitial [12, 14].

#### D. Bile Duct

Postoperative radiotherapy may be helpful in patients with positive margins or positive nodes. Intraluminal or interstitial brachytherapy can be used as a boost following external-beam radiotherapy to areas of close or positive margin. External-beam radiotherapy plus brachytherapy can be effective palliation for patients with unresectable disease. There is evidence that radiotherapy can provide long-term local control and that dose escalation with brachytherapy may be important to yield improved outcomes. Intraluminal brachytherapy alone can be used to palliate biliary obstruction along with percutaneous drainage [25-27].

# E. Esophagus

HDR intraluminal brachytherapy has been used in the treatment of esophageal cancer, both for palliation and as a component of a definitive regimen [28]. In the definitive setting, HDR brachytherapy has most commonly been used in combination with external-beam radiotherapy, though brachytherapy alone may be adequate in the subset of cancers confined to the mucosal layer of the esophagus [29-31]. The improvement in local control with the addition of HDR brachytherapy must be balanced against the risk for treatment-related morbidity in each individual case.

# F. Lung/Bronchus/Trachea

HDR brachytherapy has been used to treat malignancies involving the central lung, bronchus, and trachea. In definitive cases, it can be used alone or in conjunction with external-beam radiotherapy [32-35]. HDR brachytherapy also has a well-established role in the palliation of primary and recurrent endobronchial lesions [36].

## G. Prostate

HDR or LDR brachytherapy may be used as monotherapy or as a boost in combination with external-beam radiotherapy for the treatment of prostate cancer. It may be used as monotherapy for select low-risk and select patients with intermediate-risk disease [37-48] (ie, favorable intermediate-risk and select unfavorable intermediate-risk) and as a boost in combination with external-beam radiotherapy for unfavorable intermediate-risk or high-risk disease. In addition, HDR brachytherapy may be used to salvage local recurrence of disease after prior definitive radiotherapy [49-54]. There is a separate <u>ACR—ABS Practice Parameter for Transperineal Permanent Brachytherapy of Prostate Cancer</u> [55].

## H. Breast

HDR brachytherapy can be used as a boost to the tumor bed after conventional external-beam

radiotherapy, and it can also be used for delivering accelerated partial breast irradiation (APBI) as the sole postoperative radiation treatment [56-60]. APBI is used for select patients with early breast cancer or in situ disease or recurrent disease. This approach treats a limited volume of breast tissue around the lumpectomy site over a short duration of time. Applicator insertion techniques include multicatheter interstitial tubes stabilized with buttons and various single-entry intracavitary devices (balloon catheters and other multichannel devices). Additionally, HDR brachytherapy can be noninvasively targeted to the lumpectomy bed by utilizing superficially placed applicators positioned with mammographic image guidance [61-65]. The role of radionuclide-based intraoperative therapy in treating early-stage disease remains an option in select circumstances [66]. In this approach, radiotherapy is administered to the tumor bed at the time of the lumpectomy procedure. Further information related to patient selection and indications is available from ASTRO and ACR documents [67, 68].

## I. Head and Neck

LDR brachytherapy has long played an important role in the treatment of head and neck malignancies. The same operative techniques may be used for HDR brachytherapy [69-80]. Tumors in the head and neck affect important anatomical structures; therefore, careful attention to the preservation of normal tissue structure and function is needed. Multi-fraction regimens that avoid large doses per fraction have been recommended[81]. Computer-based dose optimization, advances in radiation safety, and improved nursing care are important reasons why LDR brachytherapy is being supplanted by HDR brachytherapy, especially in head and neck brachytherapy where nursing care is so important to patient comfort and quality outcomes [40, 82-87]. Interstitial, intracavitary, surface applications, and intraoperative techniques are applicable techniques. Head and neck brachytherapy may be applied as a boost treatment in combination with external-beam radiotherapy as definitive therapy or as monotherapy in the postoperative setting in the event of close or positive margins. It may be used in any sites in the head and neck as primary curative treatment, as salvage therapy, or for reirradiation [88].

## J. Soft-Tissue Sarcoma

HDR brachytherapy has a role in the treatment of soft-tissue sarcoma, typically as part of a multidisciplinary management plan with surgery as the primary intervention. It can be a part of definitive therapy [89-97], postoperative adjuvant therapy [98-100], intraoperative radiotherapy [90, 101-103], and palliative treatment.

#### K. Pediatric Tumors

HDR brachytherapy can be useful in managing pediatric tumors. There are potential long-term consequences of irradiation in the pediatric patient, which should be a primary consideration in treatment planning along with local disease control. With its advantageous dose distribution, there are major advantages to HDR brachytherapy for avoiding irradiation to normal tissue and growth centers in the pediatric population .

### L. Skin

Although skin cancer can be treated using a variety of radiotherapy techniques, HDR brachytherapy offers unique dosimetric properties that may be useful for treating skin cancer over irregularly shaped and difficult-to-access skin surfaces [104-108]. Both interstitial and plesiotherapy (surface applicators) techniques can be used and allow for safe hypofractionation of the treatment course. HDR brachytherapy can also be used in combination with surgery for keloids [109-111].

# M. Intraoperative Brachytherapy

HDR brachytherapy catheters and/or other devices can be inserted at the time of open or laparoscopic surgery. Such devices can be left in place for postoperative simulation dosimetry and fractionated treatment delivery in a brachytherapy suite or shielded room. The advantages of the fractionated approach are time allocation for wound healing, obtaining simulation imaging, achieving good dosimetry, and the dose fractionation for normal tissue tolerance. Alternatively, in a shielded operating room, applicators can be inserted after maximum tumor resection, and a single HDR fraction can be given to the surgical margin while the tumor bed is accessible and normal tissues can be displaced or shielded from the site of

treatment. Special intraoperative applicators have been developed that conform to various tumor bed configurations. These techniques may be used in a variety of tumor types and body sites [112, 113].

#### N. Anorectal

Interstitial, intraluminal, or intraoperative HDR brachytherapy may be used in the treatment of anal and rectal cancers. This modality can be part of a preoperative approach for resectable or locally advanced rectal cancers[114, 115] or for unresectable, inoperable, and recurrent disease. For anorectal cancers, HDR brachytherapy can be used as a boost after external-beam radiotherapy [116] or as definitive treatment in selected cases. Both interstitial and intracavitary techniques have been used.

## O. Other Indications

The list of indications above is not comprehensive or exclusive. Brachytherapy can be applied and radiation accurately delivered to any site where there is localized disease. The indication may be curative or palliative. The individual radiation oncologist may find HDR brachytherapy beneficial in a variety of other tumor types and specific clinical situations (eg, penis, bladder, urethra, vulva, central nervous system, ocular).

# **V. EQUIPMENT**

HDR brachytherapy treatment is delivered with computerized robotic devices (remote afterloading devices) for reasons of radiation safety and precision of treatment delivery. They consist of a small radiation source of high specific activity attached to the end of a fine cable, a radiation-safe container, a motor drive, and sophisticated computer equipment for reliable execution of complex radiation treatment plans (ie, instructions for where and how long the radiation source should be deployed). Equipment manufacturers offer a wide range of applicators for interstitial, intracavitary, intraluminal, and surface brachytherapy. The radiation source must be changed routinely (usually every few months depending on the radionuclide used ) to account for radioactive decay, and a maintenance contract is essential to ensure the equipment functions safely and correctly. A schedule of updating and replacing the applicators and transfer tubes should be implemented to address issues of wear and aging equipment. Computerized treatment planning is accomplished with specialized hardware and highly technical software compatible with the respective HDR brachytherapy system being used.

Periodic scheduled preventive maintenance is essential. The Qualified Medical Physicist supervising the quality improvement program is responsible for documenting the maintenance and repair of remote afterloading units, applicators, transfer tubes, and other equipment (see the <u>ACR—AAPM Technical Standard for the Performance of High-Dose-Rate Brachytherapy Physics</u>)[7].

## VI. PATIENT AND PERSONNEL SAFETY

Patient protection measures include those related to medical safety and radiation protection.

- A. Patient protection measures should include the following:
  - 1. A radiation exposure monitoring program as required by the NRC or appropriate state agencies
  - 2. Annual (re)training of staff in emergency procedures in case of equipment malfunction and in brachytherapy-specific quality management procedures
  - 3. Charting systems for dose specification, definition, and delivery of treatment parameters and recording and summary of HDR brachytherapy and external-beam radiotherapy treatment
  - 4. A physics quality assurance program for ensuring accurate dose delivery to the patient
  - 5. A system for the radiation oncologist and Qualified Medical Physicist to verify independently (by another person or another method) all brachytherapy parameters to be used in each procedure (source model, radionuclide source strength activity, total dose, treatment duration, etc.) prior to HDR brachytherapy treatment delivery
  - 6. Routine leak testing of all sealed sources as required by regulatory agencies
  - 7. Use of a hand-held radiation survey meter when initially entering the room before and after a source
- B. Personnel concern measures should include the following:

- 1. A radiation exposure monitoring program as required by the NRC or appropriate state agencies
- 2. Routine leak testing of all sealed sources as required by regulatory agencies
- 3. Use of a hand-held radiation survey meter when initially entering the room before and after a source run
- 4. Appropriate safety equipment for use of sealed sources

#### VII. DOCUMENTATION

Reporting should be in accordance with the <u>ACR-ARS Practice Parameter for Communication: Radiation Oncology</u> [2].

## VIII. QUALITY CONTROL AND IMPROVEMENT, SAFETY, INFECTION CONTROL, AND PATIENT EDUCATION

Policies and procedures related to quality, patient education, infection control, and safety should be developed and implemented in accordance with the ACR Policy on Quality Control Improvement, Safety, Infection Control, and Patient Education appearing under the heading ACR Position Statement on Quality Control and Improvement, Safety, Infection Control and Patient Education on the ACR website (<a href="https://www.acr.org/Advocacy-and-Economics/ACR-Position-Statements/Quality-Control-and-Improvement">https://www.acr.org/Advocacy-and-Economics/ACR-Position-Statements/Quality-Control-and-Improvement</a> ).

## IX. SUMMARY

HDR brachytherapy is an important modality in the treatment of a variety of different malignancies. Its use allows for application of high doses of radiation to defined target volumes and allows relative sparing of adjacent critical structures. Coordination between the radiation oncologist and treatment planning staff and effective quality assurance procedures are important components of successful HDR brachytherapy programs.

#### **ACKNOWLEDGEMENTS**

This practice parameter was revised according to the process described under the heading *The Process for Developing ACR Practice Parameters and Technical Standards* on the ACR website (<a href="https://www.acr.org/Clinical-Resources/Practice-Parameters-and-Technical-Standards">https://www.acr.org/Clinical-Resources/Practice-Parameters-and-Technical-Standards</a>) by the Committee on Practice Parameters — Radiation Oncology of the ACR Commission on Radiation Oncology in collaboration with the ABS and ARS.

Writing Committee – members represent their societies in the initial and final revision of this practice parameter

<u>ACR</u> <u>ARS</u>

Saeed, Hina MD, Chair Glaser, Scott MD

Davis, Brian J MD, PhD Gorabchi, Amir Sadeghi PhD Frank, Steven J MD Mohamad, Osama MD, PhD

Sharma, Navesh DO

<u>ABS</u>

Krauss, Daniel MD

## <u>Committee on Practice Parameters – Radiation Oncology</u>

(ACR Committee responsible for sponsoring the draft through the process)

Chao, Samuel MD, Chair

Davis, Brian J MD, PhD

Frank, Steven J MD

Garsa, Adam MD

Morris, Zachary MD

Berkowitz, Aviva MD

Farach, Andrew M MD

Freedman, Laura MD

Lo, Simon S. ChB, MB

Rabatic, Bryan MD

Schechter, Naomi MD Sio, Terence Tai-Weng MD, MS

Ziemer, Benjamin MS, PhD

# **Committee on Practice Parameters and Technical Standards**

(ACR Committee responsible for sponsoring the draft through the process)

Small, William MD, Chair, Commission on Radiation Oncology

# **Comments Reconciliation Committee**

Caplin, Drew M MD

Davis, Brian J MD, PhD

Chao, Samuel MD

Frank, Steven J MD

Glaser, Scott MD Gorabchi, Amir Sadeghi PhD
Krauss, Daniel MD Mohamad, Osama MD, PhD

Saeed, Hina MD Sharma, Navesh DO

Small, William MD

#### **REFERENCES**

- **0.** American College of Radiology. ACR Practice Parameter for Continuing Medical Education. Available at https://gravitas.acr.org/PPTS/GetDocumentView?docId=130+&releaseId=2
- 1. Devlin PM. Brachytherapy Applications and Techniques. Philadelphia, PA: Lippincott Williams & Wilkins; 2006.
- **2.** American College of Radiology. ACR-ARS Practice Parameter for Communication: Radiation Oncology. Available at https://gravitas.acr.org/PPTS/GetDocumentView?docId=199+&releaseId=2
- **3.** American College of Radiology. ACR-ARS Practice Parameter for Radiation Oncology. Available at https://gravitas.acr.org/PPTS/GetDocumentView?docId=200+&releaseId=2
- **4.** American College of Radiology. ACR-ARS Practice Parameter on Informed Consent- Radiation Oncology. Available at https://gravitas.acr.org/PPTS/GetDocumentView?docId=141+&releaseId=2
- **5.** United States Nuclear Regulatory Commission. Part 35 medical use of byproduct material. Available at: http://www.nrc.gov/reading-rm/doc-collections/cfr/part035/. .
- **6.** United States Nuclear Regulatory Commission. § 35.40 Written directives. Available at: http://www.nrc.gov/reading-rm/doc-collections/cfr/part035/. .
- **7.** ACR-AAPM Technical Standard for the Performance of High-Dose-Rate Brachytherapy Physics. Available at https://gravitas.acr.org/PPTS/GetDocumentView?docld=82+&releaseId=2
- **8.** GillBeant SBSDepartment of Radiation Oncology, Magee-Womens Hospital of University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania., LinJeff FJFDepartment of Gynecologic Oncology, Magee-Womens Hospital of University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania., KrivakThomas CTCDepartment of Gynecologic Oncology, Western Pennsylvania Hospital, Pittsburgh, Pennsylvania., et al. National Cancer Data Base analysis of radiation therapy consolidation modality for cervical cancer: the impact of new technological advancements. Int J Radiat Oncol Biol Phys 90:1083-90, .
- **9.** KarlssonJohannesJDepartment of Oncology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden., DreifaldtAnn-CharlotteACDepartment of Oncology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden., MordhorstLouise BohrLBDepartment of Oncology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden., SorbeBengtBDepartment of Oncology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden. Electronic address: bengt.sorbe@regionorebrolan.se.. Differences in outcome for cervical cancer patients treated with or without brachytherapy. Brachytherapy 16:133-140, .
- **10.** Viswanathan AN, Dimopoulos J, Kirisits C, Berger D, Potter R. Computed tomography versus magnetic resonance imaging-based contouring in cervical cancer brachytherapy: results of a prospective trial and preliminary guidelines for standardized contours. Int J Radiat Oncol Biol Phys. 2007;68(2):491-498.
- **11.** Haie-MederChristineCDepartment of Radiotherapy, Brachytherapy Unit, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France., PötterRichardR, Van LimbergenErikE, et al. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiother Oncol 74:235-45, .
- **12.** Beriwal S, Demanes DJ, Erickson B, et al. American Brachytherapy Society consensus guidelines for interstitial brachytherapy for vaginal cancer. Brachytherapy. 11(1):68-75, 2012 Jan-Feb.
- **13.** Fayed A, Mutch DG, Rader JS, et al. Comparison of high-dose-rate and low-dose-rate brachytherapy in the treatment of endometrial carcinoma. Int J Radiat Oncol Biol Phys. 2007;67(2):480-484.
- 14. Frank SJ, Jhingran A, Levenback C, Eifel PJ. Definitive radiation therapy for squamous cell carcinoma of the

vagina. Int J Radiat Oncol Biol Phys. 2005; 62(1):138-147.

- **15.** HarkenriderMatthew MMMDepartment of Radiation Oncology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL. Electronic address: mharkenrider@lumc.edu., BlockAlec MAMDepartment of Radiation Oncology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL., AlektiarKaled MKMDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY., et al. American Brachytherapy Task Group Report: Adjuvant vaginal brachytherapy for early-stage endometrial cancer: A comprehensive review. Brachytherapy 16:95-108, .
- **16.** Harkenrider MM, Grover S, Erickson BA, et al. Vaginal brachytherapy for postoperative endometrial cancer: 2014 Survey of the American Brachytherapy Society. Brachytherapy. 2016;15(1):23-9. doi: 10.1016/j.brachy.2015.09.012. Epub 2015 Nov 24.
- **17.** Klopp A, Smith BD, Alektiar K, et al. The role of postoperative radiation therapy for endometrial cancer: Executive summary of an American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol. 2014;4(3):137-144.
- **18.** Pearcey RG, Petereit DG. Post-operative high dose rate brachytherapy in patients with low to intermediate risk endometrial cancer. Radiother Oncol. 2000 Jul;56(1):17-22.
- **19.** Schwarz JK, Beriwal S, Esthappan J, et al. Consensus statement for brachytherapy for the treatment of medically inoperable endometrial cancer. Brachytherapy. 14(5):587-99, 2015 Sep-Oct. Brachytherapy. 14(5):587-99, 2015 Sep-Oct.
- **20.** Small W, Jr., Beriwal S, Demanes DJ, et al. American Brachytherapy Society consensus guidelines for adjuvant vaginal cuff brachytherapy after hysterectomy. Brachytherapy. 2012; 11(1):58-67.
- **21.** SmallWilliamWJrDivision of Radiation Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60611, USA. w-small@northwestern.edu, EricksonBethB, KwakwaFrancisF. American Brachytherapy Society survey regarding practice patterns of postoperative irradiation for endometrial cancer: current status of vaginal brachytherapy. Int J Radiat Oncol Biol Phys 63:1502-7, .
- **22.** Harkenrider MM, Alite F, Silva SR, Small W Jr. Image-Based Brachytherapy for the Treatment of Cervical Cancer. [Review]. Int J Radiat Oncol Biol Phys. 92(4):921-34, 2015 Jul 15.
- **23.** PötterRichardRDepartment of Radiation Oncology, Comprehensive Cancer Center, Christian Doppler Laboratory for Medical Radiation Research for Radiation Oncology, Medical University of Vienna, Austria., TanderupKariKDepartment of Oncology, Aarhus University Hospital, Denmark., KirisitsChristianCDepartment of Radiation Oncology, Comprehensive Cancer Center, Christian Doppler Laboratory for Medical Radiation Research for Radiation Oncology, Medical University of Vienna, Austria., et al. The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies. Clin Transl Radiat Oncol 9:48-60, .
- **24.** SturdzaAlinaAMedical University of Vienna, Comprehensive Cancer Center, Department of Radiation Oncology, Austria., PötterRichardRMedical University of Vienna, Comprehensive Cancer Center, Department of Radiation Oncology, Austria. Electronic address: richard.poetter@meduniwien.ac.at., FokdalLars UlrikLUAarhus University Hospital, Department of Oncology, Denmark., et al. Image guided brachytherapy in locally advanced cervical cancer: Improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study. Radiother Oncol 120:428-433, .
- **25.** Crane CH, Macdonald KO, Vauthey JN, et al. Limitations of conventional doses of chemoradiation for unresectable biliary cancer. Int J Radiat Oncol Biol Phys. 2002 Jul 15;53(4):969-74.
- **26.** CzitoBrian GBGDepartment of Radiation Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA., AnscherMitchell SMS, WillettChristopher GCG. Radiation therapy in the treatment of cholangiocarcinoma. Oncology (Williston Park) 20:873-84; discussion 886-8, 893-5, .
- **27.** Erickson B, Subir N. Extrahepatic bile duct and liver cancer. In: Nag S, ed. Principles and Practice of Brachytherapy. Armonk, NY: Futura Publishing Co.; 1997:367-91.
- **28.** Sur RK, Levin CV, Donde B, Sharma V, Miszczyk L, Nag S. Prospective randomized trial of HDR brachytherapy as a sole modality in palliation of advanced esophageal carcinoma--an International Atomic Energy Agency study. Int J Radiat Oncol Biol Phys. 2002 May 01;53(1):127-33.
- **29.** BrunnerThomas BTBDepartment of Radiation Therapy, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen. thomas.brunner@rob.ox.ac.uk, RuppAndreasA, MelznerWinfridW, GrabenbauerGerhard GGG, SauerRolfR. Esophageal cancer. A prospective phase II study of concomitant-boost external-beam chemoradiation with a top-up endoluminal boost. Strahlenther Onkol 184:15-22, .
- **30.** MurakamiYujiYDepartment of Radiation Oncology, Hiroshima University Graduate School of Biomedical Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan. yujimura@hiroshima-u.ac.jp, NagataYasushiY, Nishibuchilkunol, et al. Long-term outcomes of intraluminal brachytherapy in combination with external beam

radiotherapy for superficial esophageal cancer. Int J Clin Oncol 17:263-71, .

- **31.** YamadaKazunariKDepartment of Therapeutic Radiology, Tenri Hospital, Nara, Japan. kyamadarad@umin.ac.jp, MurakamiMasaoM, OkamotoYoshiakiY, et al. Treatment results of chemoradiotherapy for clinical stage I (T1N0M0) esophageal carcinoma. Int J Radiat Oncol Biol Phys 64:1106-11, .
- **32.** Aumont-le GuilcherMaudMCentre René Gauducheau, Nantes, France., PrevostBernardB, SunyachMarie PierreMP, et al. High-dose-rate brachytherapy for non-small-cell lung carcinoma: a retrospective study of 226 patients. Int J Radiat Oncol Biol Phys 79:1112-6, .
- **33.** HennequinChristopheCService de Cancérologie-Radiothérapie, Hôpital Saint-Louis, Paris, France. christophe.hennequin@sls.ap-hop-paris.fr, BleichnerOlivierO, TrédanielJeanJ, et al. Long-term results of endobronchial brachytherapy: A curative treatment?. Int J Radiat Oncol Biol Phys 67:425-30, .
- **34.** KawamuraHidemasaHDepartment of Radiation Oncology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan. kawa@gunma-u.ac.jp, EbaraTakeshiT, KatohHiroyukiH, et al. Long-term results of curative intraluminal high dose rate brachytherapy for endobronchial carcinoma. Radiat Oncol 7:112, .
- **35.** NiemoellerOlivier MOMDepartment of Radiotherapy and Radiation Oncology, Ludwig-Maximilians University Munich, Marchioninistr, 15, 81377 Munich, Germany. olivier.niemoeller@med.uni-muenchen.de, PöllingerBarbaraB, NiyaziMaximilianM, et al. Mature results of a randomized trial comparing two fractionation schedules of high dose rate endoluminal brachytherapy for the treatment of endobronchial tumors. Radiat Oncol 8:8, .
- **36.** OzkokSerdarSEge University, Faculty of Medicine, Department of Radiation Oncology, Izmir, Turkey., Karakoyun-CelikOmurO, GokselTuncayT, et al. High dose rate endobronchial brachytherapy in the management of lung cancer: response and toxicity evaluation in 158 patients. Lung Cancer 62:326-33, .
- **37.** Corner C, Rojas AM, Bryant L, Ostler P, Hoskin P. A Phase II study of high-dose-rate afterloading brachytherapy as monotherapy for the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008; 72(2):441-446.
- **38.** DemanesD JeffreyDJDepartment of Radiation Oncology, University of California Los Angeles, Los Angeles, CA., GhilezanMichel IMIDepartment of Radiation Oncology, Michigan Healthcare Professionals/21 Century Oncology, Pontiac, MI. Electronic address: mghileza@rtsx.com.. High-dose-rate brachytherapy as monotherapy for prostate cancer. Brachytherapy 13:529-41, .
- **39.** HoskinPeterPCancer Centre, Mount Vernon Hospital, Northwood, UK., RojasAnaACancer Centre, Mount Vernon Hospital, Northwood, UK. Electronic address: arc03@btconnect.com., OstlerPeterPCancer Centre, Mount Vernon Hospital, Northwood, UK., et al. High-dose-rate brachytherapy with two or three fractions as monotherapy in the treatment of locally advanced prostate cancer. Radiother Oncol 112:63-7, .
- **40.** Yamazaki H, Inoue T, Yoshida K, et al. Brachytherapy for early oral tongue cancer: low dose rate to high dose rate. J Radiat Res. 2003 Mar;44(1):37-40.
- **41.** DemanesD JeffreyDJCalifornia Endocurietherapy Cancer Center, Oakland, CA, USA. jdemanes@cetmc.com, RodriguezRodney RRR, SchourLionelL, BrandtDavidD, AltieriGillianG. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results. Int J Radiat Oncol Biol Phys 61:1306-16, .
- **42.** GalalaeRazvan MRMMedical Faculty, Christian-Albrechts-University Kiel, Kiel, Germany. Electronic address: galalae@evk-ge.de., ZakikhanyNuria HelenaNHMedical Faculty, Christian-Albrechts-University Kiel, Kiel, Germany., GeigerFriedemannFDepartment of Pediatrics, Christian-Albrechts-University Kiel, Kiel, Germany., et al. The 15-year outcomes of high-dose-rate brachytherapy for radical dose escalation in patients with prostate cancer a benchmark for high-tech external beam radiotherapy alone?. Brachytherapy 13:117-22, .
- **43.** RogersC LelandCLGammaWest Cancer Services, Salt Lake City, Utah, USA. Leland@GammaWest.com, AlderStephen CSC, RogersR LeGrandRL, et al. High dose brachytherapy as monotherapy for intermediate risk prostate cancer. J Urol 187:109-16, .
- **44.** YoshiokaYasuoYDepartment of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, Japan., SuzukiOsamuODepartment of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, Japan., OtaniYukiYDepartment of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, Japan., YoshidaKenKDepartment of Radiology, Osaka Medical College, Osaka, Japan., NoseTakayukiTDepartment of Radiation Oncology, Nippon Medical School Tama Nagayama Hospital, Tokyo, Japan.,
- OgawaKazuhikoKDepartment of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, Japan.. High-dose-rate brachytherapy as monotherapy for prostate cancer: technique, rationale and perspective. J Contemp Brachytherapy 6:91-8, .
- **45.** ZamboglouNikolaosNDepartment of Radiation Oncology, Klinikum Offenbach, Offenbach, Germany., TselisNikolaosN, BaltasDimosD, et al. High-dose-rate interstitial brachytherapy as monotherapy for clinically

localized prostate cancer: treatment evolution and mature results. Int J Radiat Oncol Biol Phys 85:672-8, . **46.** JawadMaha SaadaMSDepartment of Radiation Oncology, Oakland University William Beaumont School of Medicine, Royal Oak, Michigan., DilworthJoshua TJTDepartment of Radiation Oncology, Oakland University William Beaumont School of Medicine, Royal Oak, Michigan., GustafsonGary SGSDepartment of Radiation Oncology, Oakland University William Beaumont School of Medicine, Royal Oak, Michigan., et al. Outcomes Associated With 3 Treatment Schedules of High-Dose-Rate Brachytherapy Monotherapy for Favorable-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys 94:657-66, .

- **47.** FrankSteven JSJDepartment of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas. Electronic address: sjfrank@mdanderson.org., PughThomas JTJDepartment of Radiation Oncology, University of Colorado School of Medicine, Aurora, Colorado., BlanchardPierrePDepartment of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas; Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France., et al. Prospective Phase 2 Trial of Permanent Seed Implantation Prostate Brachytherapy for Intermediate-Risk Localized Prostate Cancer: Efficacy, Toxicity, and Quality of Life Outcomes. Int J Radiat Oncol Biol Phys 100:374-382, .
- 48. KukielkaAndrzej MarekAMDepartment of Radiotherapy, Centrum Onkologii Instytut im. M. Sklodowskiej-Curie, Oddzial w Krakowie, Kraków, Poland. Electronic address: drkukielka@gmail.com., DabrowskiTomaszTDepartment of Radiotherapy, Centrum Onkologii Instytut im. M. Sklodowskiej-Curie, Oddzial w Krakowie, Kraków, Poland., WalasekTomaszTDepartment of Radiotherapy, Centrum Onkologii Instytut im. M. Sklodowskiej-Curie, Oddzial w Krakowie, Kraków, Poland., OlchawaAgnieszkaADepartment of Radiotherapy, Szpital Specjalistyczny im J. Sniadeckiego, Nowy Sacz, Poland., KudziaRoksanaRDepartment of Medical Physics, Centrum Onkologii Instytut im. M. Sklodowskiej-Curie, Oddzial w Krakowie, Kraków, Poland., DybekDorotaDDepartment of Medical Physics, Centrum Onkologii Instytut im. M. Sklodowskiej-Curie, Oddzial w Krakowie, Kraków, Poland.. High-dose-rate brachytherapy as a monotherapy for prostate cancer--Single-institution results of the extreme fractionation regimen. Brachytherapy 14:359-65, .
- **49.** ChenChien PeterCPDepartment of Radiation Oncology, Scripps Clinic, San Diego, California, USA., WeinbergVivianV, ShinoharaKatsutoK, et al. Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes. Int J Radiat Oncol Biol Phys 86:324-9, .
- **50.** YamadaYoshiyaYDepartment of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY. Electronic address: yamadaj@mskcc.org., KollmeierMarisa AMADepartment of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY., PeiXinXDepartment of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY., et al. A Phase II study of salvage high-dose-rate brachytherapy for the treatment of locally recurrent prostate cancer after definitive external beam radiotherapy. Brachytherapy 13:111-6, .
- **51.** Jiang P, van der Horst C, Kimmig B, et al. Interstitial high-dose-rate brachytherapy as salvage treatment for locally recurrent prostate cancer after definitive radiation therapy: Toxicity and 5-year outcome. Brachytherapy. 16(1):186-192, 2017 Jan Feb.
- **52.** Murgic J, Morton G, Loblaw A, et al. Focal Salvage High Dose-Rate Brachytherapy for Locally Recurrent Prostate Cancer After Primary Radiation Therapy Failure: Results From a Prospective Clinical Trial. Int J Radiat Oncol Biol Phys. 102(3):561-567, 2018 11 01.
- **53.** Resch A, Pötter R, Van Limbergen E, et al. Long-term results (10 years) of intensive breast conserving therapy including a high-dose and large-volume interstitial brachytherapy boost (LDR/HDR) for T1/T2 breast cancer. Radiother Oncol. 2002 Apr;63(1):47-58.
- **54.** SchroederThomas MTMUNM Cancer Center, The University of New Mexico, Albuquerque, NM 87131-0001, USA. tschroeder@salud.unm.edu, LiemBenB, SampathSagusS, ThompsonWilliam RWR, LonghurstJanetJ, RoyceMelanieM. Early breast cancer with positive margins: excellent local control with an upfront brachytherapy boost. Breast Cancer Res Treat 134:719-25, .
- **55.** American College of Radiology. ACR-ABS-ARS Practice Parameter for Transperineal Permanent Brachytherapy of Prostate Cancer. Available at https://gravitas.acr.org/PPTS/GetDocumentView?docId=70+&releaseId=2
- **56.** BenitezPamela RPRDepartment of Surgery, William Beaumont Hospital, 3577 W. 13 Mile Rd, Suite 201, Beaumont Cancer Center, Royal Oak, MI 48073, USA. pbenitez@beaumont.edu, KeischMartin EME, ViciniFrankF, et al. Five-year results: the initial clinical trial of MammoSite balloon brachytherapy for partial breast irradiation in early-stage breast cancer. Am J Surg 194:456-62, .
- **57.** Shah C, Vicini F, Shaitelman SF, et al. The American Brachytherapy Society consensus statement for accelerated partial-breast irradiation. Brachytherapy. 17(1):154-170, 2018 Jan Feb.
- **58.** ColesCharlotte ECEDepartment of Oncology, University of Cambridge, Cambridge, UK. Electronic address: colesc@doctors.org.uk., GriffinClare LCLClinical Trials and Statistics Unit, The Institute of Cancer Research, London,

- UK., KirbyAnna MAMDepartment of Radiotherapy and Imaging, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK., et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet 390:1048-1060, .
- **59.** SchäferRebekkaRDepartment of Radiation Oncology, University Hospital Würzburg, Würzburg, Germany. Electronic address: schaefer\_r2@ukw.de., StrnadVratislavVDepartment of Radiation Oncology, University Hospital Erlangen, Germany., PolgárCsabaCCenter of Radiotherapy, National Institute of Oncology, Budapest, Hungary; Department of Oncology, Semmelweis University, Budapest, Hungary., et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncol 19:834-844, .
- **60.** StrnadVratislavVDepartment of Radiation Oncology, University Hospital Erlangen, Erlangen, Germany. vratislav.strnad@uk-erlangen.de, HildebrandtGuidoG, PötterRichardR, et al. Accelerated partial breast irradiation: 5-year results of the German-Austrian multicenter phase II trial using interstitial multicatheter brachytherapy alone after breast-conserving surgery. Int J Radiat Oncol Biol Phys 80:17-24, .
- **61.** HamidSubarnaSDepartment of Radiation Oncology, Tufts Medical Center, Tufts University School of Medicine, Boston, MA, USA. shamid@tuftsmedicalcenter.org, RocchioKathyK, ArthurDouglasD, et al. A multi-institutional study of feasibility, implementation, and early clinical results with noninvasive breast brachytherapy for tumor bed boost. Int J Radiat Oncol Biol Phys 83:1374-80, .
- **62.** LeonardKara LynneKLDepartment of Radiation Oncology, Rhode Island Hospital, Brown Alpert Medical School, Providence, RI; Department of Radiation Oncology, Tufts Medical Center, Tufts University School of Medicine, Boston, MA. Electronic address: karalynne.kerr@gmail.com., HepelJaroslaw TJT, StyczynskiJohn RJR, HiattJessica RJR, DipetrilloThomas ATA, WazerDavid EDE. Breast boost using noninvasive image-guided breast brachytherapy vs. external beam: a 2:1 matched-pair analysis. Clin Breast Cancer 13:455-9, .
- **63.** HepelJaroslaw TJTDepartment of Radiation Oncology, Rhode Island Hospital, Brown University, Providence, RI; Department of Radiation Oncology, Tufts Medical Center, Tufts University, Boston, MA. Electronic address: jhepel@lifespan.org., HiattJessica RJRDepartment of Radiation Oncology, Rhode Island Hospital, Brown University, Providence, RI., ShaSandraSDepartment of Radiation Oncology, Watson Clinic, Lakeland, FL., et al. The rationale, technique, and feasibility of partial breast irradiation using noninvasive image-guided breast brachytherapy. Brachytherapy 13:493-501, .
- **64.** Hepel JT, Yashar C, Leonard KL, et al. Five fraction accelerated partial breast irradiation using noninvasive image-guided breast brachytherapy: Feasibility and acute toxicity. Brachytherapy. 17(5):825-830, 2018 Sep Oct.
- **65.** SchusterJessicaJDepartment of Radiation Oncology, Virginia Commonwealth University, Richmond, VA. Electronic address: Jessica.moore84@hotmail.com., ChipkoChristopherCDepartment of Radiation Oncology, Virginia Commonwealth University, Richmond, VA., KasperMichaelMSchmidt College of Medicine, FAU Lynn Cancer Institute, Boca Raton, FL., et al. Updated feasibility and reproducibility results of multi-institutional study of noninvasive breast tumor bed boost. Brachytherapy 15:804-811, .
- **66.** Vaidya JJ, Bulsara MM, Wenz FF, et al. The TARGIT-A Randomized Trial: TARGIT-IORT Versus Whole Breast Radiation Therapy: Long-Term Local Control and Survival. Int J Radiat Oncol Biol Phys 115:77-82, .
- **67.** Smith BD, Arthur DW, Buchholz TA, et al. Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys. 2009;74(4):987-1001.
- **68.** WhiteJulia RJRDepartment of Radiation Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin 53226-4801, USA. jwhite@mcw.edu, HalbergFrancine EFE, RabinovitchRachelR, et al. American College of Radiology appropriateness criteria on conservative surgery and radiation: stages I and II breast carcinoma. J Am Coll Radiol 5:701-13, .
- **69.** HarrisonL BLBDepartment of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA., LeeH JHJ, PfisterD GDG, et al. Long term results of primary radiotherapy with/without neck dissection for squamous cell cancer of the base of tongue. Head Neck 20:668-73, .
- **70.** HarrisonL BLBDepartment of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021., ZelefskyM JMJ, ArmstrongJ GJG, CarperEE, GaynorJ JJJ, SessionsR BRB. Performance status after treatment for squamous cell cancer of the base of tongue--a comparison of primary radiation therapy versus primary surgery. Int J Radiat Oncol Biol Phys 30:953-7, .
- **71.** CanoElmer RERDepartment of Radiation Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213, USA., LaiStephen YSY, CaylakliFatmaF, et al. Management of squamous cell carcinoma of the base of tongue with chemoradiation and brachytherapy. Head Neck 31:1431-8, .
- 72. LevendagPeterPDepartment of Radiation Oncology, Erasmus Medical Center, Daniel den Hoed Cancer Center,

Rotterdam, The Netherlands. p.levendag@erasmusmc.nl, NijdamWidekeW, NoeverIngeI, et al. Brachytherapy versus surgery in carcinoma of tonsillar fossa and/or soft palate: late adverse sequelae and performance status: can we be more selective and obtain better tissue sparing?. Int J Radiat Oncol Biol Phys 59:713-24, .

- **73.** LevendagPeter CPCDepartment of Radiation-Oncology, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands. p.levendag@erasmusmc.nl, NijdamWideke MWM, van MoolenburghSanne ESE, et al. Interstitial radiation therapy for early-stage nasal vestibule cancer: a continuing quest for optimal tumor control and cosmesis. Int J Radiat Oncol Biol Phys 66:160-9, .
- **74.** Martínez-MongeRafaelRDepartment of Oncology, Clínica Universitaria de Navarra, Pamplona, Spain. rmartinezm@unav.es, Pagola DivassónMaríaM, CambeiroMauricioM, et al. Determinants of complications and outcome in high-risk squamous cell head-and-neck cancer treated with perioperative high-dose rate brachytherapy (PHDRB). Int J Radiat Oncol Biol Phys 81:e245-54, .
- **75.** MatsumotoKeijiK\*Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. shioyama@radiol.med.kyushu-u.ac.jp., SasakiTomonariT, ShioyamaYoshiyukiY, et al. Treatment outcome of high-dose-rate interstitial radiation therapy for patients with stage I and II mobile tongue cancer. Jpn J Clin Oncol 43:1012-7, .
- **76.** Mazeron JJ, Ardiet JM, Haie-Meder C, et al. GEC-ESTRO recommendations for brachytherapy for head and neck squamous cell carcinomas. Radiother Oncol. 2009;91(2):150-156.
- **77.** Pernot M, Hoffstetter S, Peiffert D, et al. Role of interstitial brachytherapy in oral and oropharyngeal carcinoma: reflection of a series of 1344 patients treated at the time of initial presentation. Otolaryngol Head Neck Surg. 1996;115(6):519-526.
- **78.** Takácsi-NagyZoltánZCenter of Radiotherapy, National Institute of Oncology, Budapest, Hungary. Electronic address: takacsi@oncol.hu., ObernaFerencF, KoltaiPálP, et al. Long-term outcomes with high-dose-rate brachytherapy for the management of base of tongue cancer. Brachytherapy 12:535-41, .
- **79.** YamazakiHideyaHDepartment of Radiology, National Hospital Organization Osaka National Hospital, Hoenzaka 2-1-14 Chuo-ku, Osaka city, Osaka 540-0006 Japan. hideya10@hotmail.com, InoueTakehiroT, YoshidaKenK, et al. Comparison of three major radioactive sources for brachytherapy used in the treatment of node negative T1-T3 oral tongue cancer: influence of age on outcome. Anticancer Res 27:491-7, .
- **80.** YamazakiHideyaHDepartment of Radiology, Kyoto Prefectural University of Medicine, 465 Kajiicho Kawaramachi Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan. hideya10@hotmail.com, YoshidaKenK, YoshiokaYasuoY, et al. High dose rate brachytherapy for oral cancer. J Radiat Res 54:1-17, .
- **81.** Nag S, Cano ER, Demanes DJ, Puthawala AA, Vikram B, The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for head-and-neck carcinoma. Int J Radiat Oncol Biol Phys. 2001 Aug 01;50(5):1190-8.
- **82.** Glatzel M, Büntzel J, Schröder D, Küttner K, Fröhlich D. High-dose-rate brachytherapy in the treatment of recurrent and residual head and neck cancer. Laryngoscope. 2002 Aug;112(8 Pt 1):1366-71.
- **83.** InoueTTDepartment of Radiation Oncology, Biomedical Research Center, Osaka University Medical School, Japan., InoueTT, TeshimaTT, et al. Phase III trial of high and low dose rate interstitial radiotherapy for early oral tongue cancer. Int J Radiat Oncol Biol Phys 36:1201-4, .
- **84.** Kakimoto N, Inoue T, Inoue T, Results of low- and high-dose-rate interstitial brachytherapy for T3 mobile tongue cancer. Radiother Oncol. 2003 Aug;68(2):123-8.
- **85.** Leung TW, Wong VY, Kwan KH, et al. High dose rate brachytherapy for early stage oral tongue cancer. Head Neck. 2002 Mar;24(3):274-81.
- **86.** PatraNiladri BNBDepartment of Radiotherapy, Medical College Hospital, Kolkata, India. Electronic address: nbpatra@yahoo.co.in., GoswamiJyotirupJDepartment of Radiotherapy, Medical College Hospital, Kolkata, India., BasuSwapnenduSDepartment of Radiotherapy, Medical College Hospital, Kolkata, India.,
- ChatterjeeKaushikKDepartment of Radiotherapy, Medical College Hospital, Kolkata, India., SarkarShyamal KSKDepartment of Radiotherapy, Medical College Hospital, Kolkata, India.. Outcomes of high dose rate interstitial boost brachytherapy after external beam radiation therapy in head and neck cancer--an Indian (single institutional) learning experience. Brachytherapy 8:248-254, .
- **87.** PellizzonAntonio Cassio AssisACRadiation Oncology Department, Hospital AC Camargo, Rua Professor Antonio Prudente, 211, Liberdade, São Paulo, Brazil. CEP 01509-010. pellizzon@aol.com, dos Santos NovaesPaulo Eduardo RibeiroPE, Conte MaiaMaria AparecidaMA, et al. Interstitial high-dose-rate brachytherapy combined with cervical dissection on head and neck cancer. Head Neck 27:1035-41, .
- **88.** HepelJaroslaw TJTDepartment of Internal Medicine, University of California at Irvine, Orange, CA 90806, USA. bvigil@memnet.org, SyedA M NisarAM, PuthawalaAjmelA, SharmaAnilA, FrankelPaulP. Salvage high-dose-rate (HDR) brachytherapy for recurrent head-and-neck cancer. Int J Radiat Oncol Biol Phys 62:1444-50, .

- **89.** GoodmanKaryn AKADepartment of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA., WoldenSuzanne LSL, LaQuagliaMichael PMP, AlektiarKaledK, D'SouzaDavidD, ZelefskyMichael JMJ. Intraoperative high-dose-rate brachytherapy for pediatric solid tumors: a 10-year experience. Brachytherapy 2:139-46, .
- **90.** Martínez-MongeRafaelRDepartment of Oncology, University Clinic, University of Navarra, Avda Pío XII s/n, Pamplona, E-31080 Navarre, Spain. rmartinezm@unav.es, GarránCristinaC, CambeiroMauricioM, San JuliánMikelM, AlcaldeJuanJ, SierrasesúmagaLuisL. Feasibility report of conservative surgery, perioperative high-dose-rate brachytherapy (PHDRB), and low-to-moderate dose external beam radiation therapy (EBRT) in pediatric sarcomas. Brachytherapy 3:196-200, .
- **91.** Nag S, Tippin D, Ruymann FB. Intraoperative high-dose-rate brachytherapy for the treatment of pediatric tumors: the Ohio State University experience. Int J Radiat Oncol Biol Phys. 2001 Nov 01;51(3):729-35.
- **92.** ItamiJunJDepartment of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan. jitami@ncc.go.jp, SumiMinakoM, BeppuYasuoY, et al. High-dose rate brachytherapy alone in postoperative soft tissue sarcomas with close or positive margins. Brachytherapy 9:349-53, .
- **93.** LaskarSiddharthaSDepartment of Radiation Oncology, Tata Memorial Hospital, Dr. Ernest Borges Road, Parel, Mumbai, India. laskars2000@yahoo.com, BahlGauravG, PuriAjayA, et al. Perioperative interstitial brachytherapy for soft tissue sarcomas: prognostic factors and long-term results of 155 patients. Ann Surg Oncol 14:560-7, .
- **94.** Nag S, Tippin D, Ruymann FB. Long-term morbidity in children treated with fractionated high-dose-rate brachytherapy for soft tissue sarcomas. J Pediatr Hematol Oncol. 2003 Jun;25(6):448-52.
- **95.** PeteraJiríJDepartment of Oncology and Radiotherapy, University Hospital Hradec Králové, Hradec Králové, Czech Republic. petera@fnhk.cz, SoumarováRenataR, RuzickováJanaJ, et al. Perioperative hyperfractionated highdose rate brachytherapy for the treatment of soft tissue sarcomas: multicentric experience. Ann Surg Oncol 17:206-10, .
- **96.** Raut C, Albert M. Soft tissue sarcoma brachytherapy. In: Devlin PM, ed. Brachytherapy Applications and Techniques. 1st ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2006.
- **97.** VianiGustavo AGARadiation Oncology Department, Hospital do Cancer A,C, Camargo, Sao Paulo, Brazil. gusviani@gmail.com, NovaesPaulo EPE, JacintoAlexandre AAA, et al. High-dose-rate brachytherapy for soft tissue sarcoma in children: a single institution experience. Radiat Oncol 3:9, .
- **98.** BöllingTobiasTDepartment of Radiotherapy, University Hospital Münster, Germany. Tobias.Boelling@ukmuenster.de, SchüllerPatrickP, DistelmaierBerndB, et al. Perioperative high-dose rate brachytherapy using a bendy applicator (flab): treatment results of 74 patients. Anticancer Res 28:3885-90, .
- **99.** Koizumi M, Inoue T, Yamazaki H, et al. Perioperative fractionated high-dose rate brachytherapy for malignant bone and soft tissue tumors. Int J Radiat Oncol Biol Phys. 1999 Mar 15;43(5):989-93.
- **100.** PoharSurjeetSDepartment of Radiation Oncology, SUNY Upstate Medical University, Syracuse, NY 23507, USA. poharss@evms.edu, HaqRashidR, LiuLizhongL, et al. Adjuvant high-dose-rate and low-dose-rate brachytherapy with external beam radiation in soft tissue sarcoma: a comparison of outcomes. Brachytherapy 6:53-7, .
- **101.** Alektiar KM, Hu K, Anderson L, Brennan MF, Harrison LB. High-dose-rate intraoperative radiation therapy (HDR-IORT) for retroperitoneal sarcomas. Int J Radiat Oncol Biol Phys. 2000 Apr 01;47(1):157-63.
- **102.** DziewirskiWirginiuszWDepartment of Soft Tissue/Bone Sarcoma, M. Sklodowska-Curie Cancer Center and Institute of Oncology, W.K. Roentgena Str. 5, Warsaw, 02-781, Poland., RutkowskiPiotrP, NoweckiZbigniew IZI, et al. Surgery combined with intraoperative brachytherapy in the treatment of retroperitoneal sarcomas. Ann Surg Oncol 13:245-52, .
- **103.** Rachbauer F, Sztankay A, Kreczy A, et al. High-dose-rate intraoperative brachytherapy (IOHDR) using flab technique in the treatment of soft tissue sarcomas. Strahlenther Onkol. 2003 Jul;179(7):480-5.
- **104.** FabriniMaria GraziaMGDepartment of Oncology, Pisa University, and Division of Radiotherapy, Azienda Ospedaliera Universitaria Pisana, via Roma 67, Pisa, Italy. m.fabrini@ao-pisa.toscana.it, PerroneFrancoF, De LiguoroMarioM, CioniniLucaL. High-dose-rate brachytherapy in a large squamous cell carcinoma of the hand. Brachytherapy 7:270-5, .
- **105.** SomanchiB VBVDepartment of Hand Surgery, Salford Royal Hospital, Salford M6 8HD, UK. brindavihari2001@yahoo.com, StantonAA, WebbMM, LoncasterJJ, AllanEE, MuirL T S WLT. Hand function after high dose rate brachytherapy for squamous cell carcinoma of the skin of the hand. Clin Oncol (R Coll Radiol) 20:691-7, .
- **106.** LipmanDjoeriDDepartment of Radiation Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands., VerhoefLia CLCDepartment of Radiation Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands., TakesRobert PRPDepartment of Otolaryngology Head and Neck Surgery,

Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands., KaandersJohannes HJHDepartment of Radiation Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands., JanssensGeert OGODepartment of Radiation Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.. Outcome and toxicity profile after brachytherapy for squamous cell carcinoma of the nasal vestibule. Head Neck 37:1297-303, .

- **107.** PopL ALAInstitute of Radiotherapy, University of Nijmegen, The Netherlands., KaandersJ HJH, HeinermanE CEC. High dose rate intracavitary brachytherapy of early and superficial carcinoma of the nasal vestibule as an alternative to low dose rate interstitial radiation therapy. Radiother Oncol 27:69-72, .
- **108.** VavassoriAndreaADepartment of Radiotherapy, IEO European Institute of Oncology IRCCS, Milan, Italy., RivaGiuliaGDepartment of Radiotherapy, IEO European Institute of Oncology IRCCS, Milan, Italy.Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy., DuranteStefanoSDepartment of Radiotherapy, IEO European Institute of Oncology IRCCS, Milan, Italy.Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy., et al. Mould-based surface high-dose-rate brachytherapy for eyelid carcinoma. J Contemp Brachytherapy 11:443-448, .
- **109.** Guix B, Henríquez I, Andrés A, Finestres F, Tello JI, Martínez A. Treatment of keloids by high-dose-rate brachytherapy: A seven-year study. Int J Radiat Oncol Biol Phys. 2001 May 01;50(1):167-72.
- 110. HoangDonDFrom the Keck School of Medicine, University of Southern California, and Cedars-Sinai Medical Center, Los Angeles, CA., ReznikRobertRFrom the Keck School of Medicine, University of Southern California, and Cedars-Sinai Medical Center, Los Angeles, CA., OrgelMattMFrom the Keck School of Medicine, University of Southern California, and Cedars-Sinai Medical Center, Los Angeles, CA., LiQuanlinQFrom the Keck School of Medicine, University of Southern California, and Cedars-Sinai Medical Center, Los Angeles, CA., MirhadiAminAFrom the Keck School of Medicine, University of Southern California, and Cedars-Sinai Medical Center, Los Angeles, CA., KulberDavid ADAFrom the Keck School of Medicine, University of Southern California, and Cedars-Sinai Medical Center, Los Angeles, CA.. Surgical Excision and Adjuvant Brachytherapy vs External Beam Radiation for the Effective Treatment of Keloids: 10-Year Institutional Retrospective Analysis. Aesthet Surg J 37:212-225, .
- **111.** VeenRonald EREDepartment of Radiotherapy, University Medical Center, Utrecht, The Netherlands. R.E.Veen@umcutrecht.nl, KalHenk BHB. Postoperative high-dose-rate brachytherapy in the prevention of keloids. Int J Radiat Oncol Biol Phys 69:1205-8, .
- **112.** Hu KS, Enker WE, Harrison LB. High-dose-rate intraoperative irradiation: current status and future directions. Semin Radiat Oncol. 2002 Jan;12(1):62-80.
- **113.** Nag S, Gunderson LL, Willett CG, Harrison LB, Calvo FA. Intraoperative irradiation with electron-beam or high-dose-rate brachytherapy. In: Gunderson LL, Willett CG, Harrison LB, Calvo FA, ed. Intraoperative Irradation: Techniques and Results. Totowa, NJ: Humana Press; 1999:111-30.
- **114.** Vuong T, Belliveau PJ, Michel RP, et al. Conformal preoperative endorectal brachytherapy treatment for locally advanced rectal cancer: early results of a phase I/II study. Dis Colon Rectum. 2002 Nov;45(11):1486-93; discussion 1493-5.
- **115.** VuongTTDepartment of Radiation Oncology, McGill University Health Centre, Montreal, Quebec, Canada. te.vuong@muhc.mcgill.ca, DevicSS, PodgorsakEE. High dose rate endorectal brachytherapy as a neoadjuvant treatment for patients with resectable rectal cancer. Clin Oncol (R Coll Radiol) 19:701-5, .
- **116.** Oehler-JänneChristophCRadiation Oncology, Zurich University Hospital, Zurich, Switzerland., SeifertBurkhardtB, LütolfUrs MUM, StuderGabrielaG, GlanzmannChristophC, Ciernikl FranklF. Clinical outcome after treatment with a brachytherapy boost versus external beam boost for anal carcinoma. Brachytherapy 6:218-26, .

\*Practice parameters and technical standards that are collaborative with only radiation oncology societies (ACR Resolution 8, 2010) or are collaborative with the American Association of Physics in Medicine (ACR Resolution 54, 2015) are approved by the ACR Council Steering Committee (CSC) and the ACR Board of Chancellors (BOC) and will not go through the ACR Council. The effective date for these CSC/BOC documents is the first day of the month following a 60-day period that begins on the date the document was approved.

Development Chronology for this Practice Parameter 1996 (Resolution 15) Revised 2000 (Resolution 23) Revised 2005 (Resolution 15) Amended 2006 (Resolution 16g, 36) Revised 2010 (Resolution 3)
Revised 2015 (Resolution 39)
Revised 2015 (CSC/BOC)
Revised 2020 (CSC/BOC)
Amended 2023 (Resolution 2c)
Revised 2025 (CSC/BOC)- Effective Date, August 1st. 2025